NCT04488354CompletedPhase 1
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 20 Jul 2020
- Start date
- Jan 2021
- Primary completion date
- Oct 2025
- Lead sponsor
- Calibr, a division of Scripps Research
- Diseases
- Diffuse large B-cell lymphoma, Follicular lymphoma, Mantle cell lymphoma, Chronic lymphocytic leukaemia
- NCT number
- NCT04488354
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 16
- From Jan 2021 to the primary completion date, Oct 2025
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no specific exclusion criteria for this study
Who the study is looking for
- All patients who received at least one CLBR001 cell dose and have either discontinued early or completed the core treatment protocol or any protocol such as a managed access protocol as applicable.
- Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| City of Hope National Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
| Masonic Cancer Center, University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Sarah Cannon Research Institute (Tennessee Oncology) Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| Weill Cornell Medical College-New York Presbyterian Hospital Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Sarah Cannon Research Institute - Texas Transplant Institute Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| University of California At San Diego Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
| Wake Forest Baptist Health Coordinator of this site? Confirm its status | Winston-Salem | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.